Rabeprazole sodium and Ventavis drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Rabeprazole sodium and Ventavis. Common interactions include cardiac arrest among females and right ventricular failure among males.

The phase IV clinical study analyzes what interactions people who take Rabeprazole sodium and Ventavis have. It is created by eHealthMe based on reports of 8 people who take Rabeprazole sodium and Ventavis from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.



On Aug, 17, 2022

8 people who take Rabeprazole sodium and Ventavis together, and have interactions are studied.


What is Rabeprazole sodium?

Rabeprazole sodium has active ingredients of rabeprazole sodium. It is often used in gastroesophageal reflux disease. eHealthMe is studying from 11,701 Rabeprazole sodium users for its effectiveness, alternative drugs and more.

What is Ventavis?

Ventavis has active ingredients of iloprost. eHealthMe is studying from 11,357 Ventavis users for its effectiveness, alternative drugs and more.

Number of Rabeprazole sodium and Ventavis reports submitted per year:

Rabeprazole sodium and Ventavis drug interactions.

Common Rabeprazole Sodium and Ventavis drug interactions by gender *:

female:

  1. Cardiac arrest
  2. Disease progression
  3. Dyspnoea
  4. Exercise tolerance decreased
  5. Gastric cancer
  6. Influenza
  7. Pulmonary arterial hypertension
  8. Pulmonary arterial pressure increased
  9. Pulmonary hypertension
  10. Respiratory arrest

male:

  1. Right ventricular failure
  2. Myalgia
  3. Renal impairment
  4. Respiratory arrest
  5. Respiratory failure
  6. Cardiac failure
  7. Chronic kidney disease
  8. Pulmonary arterial hypertension
  9. Anaemia
  10. Diarrhoea

Common Rabeprazole Sodium and Ventavis drug interactions by age *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

  1. Cardiac arrest
  2. Disease progression
  3. Dyspnoea
  4. Exercise tolerance decreased
  5. Pulmonary arterial hypertension
  6. Pulmonary arterial pressure increased
  7. Respiratory arrest
  8. Respiratory failure
  9. Right ventricular failure

60+:

  1. Right ventricular failure
  2. Myalgia
  3. Renal impairment
  4. Respiratory arrest
  5. Respiratory failure
  6. Gastric cancer
  7. Influenza
  8. Respiratory disorder
  9. Cardiac failure
  10. Chronic kidney disease

* Approximation only. Some reports may have incomplete information.

Do you take Rabeprazole sodium and Ventavis?

Personalize this study to your gender and age

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.



Related studies

Alternative drugs to, pros and cons of the 2 drugs:

Browse all drug interactions of Rabeprazole sodium and Ventavis:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Rabeprazole sodium interactions:

Browse all interactions between Rabeprazole sodium and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Ventavis interactions:

Browse all interactions between Ventavis and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on rabeprazole sodium and iloprost (the active ingredients of Rabeprazole sodium and Ventavis, respectively), and Rabeprazole sodium and Ventavis (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study. Patients in the study may take other drugs besides Rabeprazole sodium and Ventavis.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: